BRACAnalysis®: Hereditary Cancer Testing for Hereditary Breast and Ovarian Cancer

BRACAnalysis^® is a genetic test that confirms the presence of a  BRCA1 or BRCA2  gene mutation. BRCA mutations are responsible for the majority of hereditary breast and ovarian cancers. People with a mutation in either the BRCA1 or BRCA2  gene  have risks of up to 87% for developing breast cancer and up to 44% for developing ovarian cancer by age 70. Mutation carriers previously diagnosed with cancer also have a significantly increased risk of developing a second primary cancer. Genetic testing, specifically the BRACAnalysis^® test, identifies patients who have these mutations.

BRACAnalysis^® is a simple blood test or oral rinse sample to find out if you have the  BRCA1 or BRCA2 mutation. Knowing the results may help you and your healthcare provider act before cancer has a chance to develop.

Benefits of BRACAnalysis^® Testing

The results of the BRACAnalysis^® test enable the development of patient-specific medical management plans to significantly reduce the risk of cancer. BRACAnalysis^® will allow you to:

Target increased surveillance and other interventions specifically to individuals with  a BRCA1 or BRCA2 mutation maximizing patient care and increasing clinical efficiency

• Significantly improve outcomes and reduce medical costs through earlier diagnosis and treatment of cancer, should it develop
• Counsel patients and family members on the underlying causes of the pattern of breast and/or ovarian cancer in their family
• Avoid unnecessary interventions for family members who do not test positive for the mutation known to be in the family

Medical Management and BRACAnalysis^®

If BRACAnalysis^® testing confirms the presence of a  BRCA1 or BRCA2 mutation , the  following medical management options may help reduce cancer risk and may either delay the onset of cancer, detect cancer at an earlier, more treatable stage or may even prevent it.

• Increased surveillance for breast cancer in mutation carriers
• Increased surveillance for ovarian cancer in mutation carriers
• Risk-reducing medications for mutation carriers
• Prophylactic surgery in mutation carriers

NOTE: Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation. While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare provider.

For more information please call us or visit https://myriad.com/products-services/hereditary-cancers/bracanalysis/ or www.myriad-oncology.com